Benny de Wit

Abstract 6921: Phosphonate-antibody-drug conjugates, a novel immunostimulatory class of ADCs driving inside-out activation of Vγ9Vδ2 T cells leading to selective tumor cell killing

Mary J. van Helden, Genny Filliciotto, Wendela A. Kappers, Diels van den Dobbelsteen et autres

Abstract Gamma delta (γδ) T cells are cytotoxic effectors capable of recognizing and eliminating tumor cells independently of major histocompatibility complex (MHC) presentation. Their presence within tumors correlates with improved clinical outcomes across various cancer types. Vγ9Vδ2 T cells, the predominant γδ …

Abstract 2934: BYON4228, an antagonistic SIRPα mAb with a unique and favorable preclinical profile compared to three comparator SIRPα mAbs

Mary van Helden, Seline A. Zwarthoff, Roel Arends, Inge Reinieren-Beeren et autres

Abstract A growing body of data from early clinical studies supports that targeting the myeloid immune checkpoint CD47-SIRPα represents a successful strategy towards establishing effective new therapies for cancer patients. Initial studies focused on CD47 blockers and more recently also SIRPα antagonistic …

nl (code pays fourni par la source)

BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells

Mary J. van Helden, Seline A. Zwarthoff, Roel J. Arends, Inge Reinieren-Beeren et autres

Background Preclinical studies have firmly established the CD47-signal-regulatory protein (SIRP)α axis as a myeloid immune checkpoint in cancer, and this is corroborated by available evidence from the first clinical studies with CD47 blockers. However, CD47 is ubiquitously expressed and mediates functional interactions …

nl (code pays fourni par la source)

Sensitivity and Drug Tolerance of Antidrug Antibody Assays in Relation to Positive Control Characteristics

David Egging, Jos Verhagen, Karin de Laat-Arts, Benny de Wit et autres

AIM: Detection and characterization of antidrug antibodies (ADA) play a key role in understanding the relation of ADA with safety and efficacy. Positive controls (PCs) are used to estimate the sensitivity and assay sensitivity in the presence of drug (drug tolerance) of …

nl (code pays fourni par la source)